OUD & Chronic Pain Management Strategies for Integrative Care

Discover the role of integrative care in managing OUD and chronic pain, as well as its impact on overall health and wellness.

Abstract

In this comprehensive educational post, I guide you through a clear, first-person narrative on modern, evidence-based strategies for treating Opioid Use Disorder (OUD) and chronic pain. Drawing on my experience as a clinician with a diverse background in chiropractic and functional medicine, I offer an in-depth exploration of the pharmacological roles of buprenorphine, methadone, and naltrexone. We will delve into the nuances of different buprenorphine formulations, their specific indications, and the critical importance of shared decision-making when initiating treatment. This article details the physiological mechanisms behind these medications, explaining the “ceiling effect” of buprenorphine, the risks of precipitated withdrawal, and innovative initiation strategies like low-dose (micro-induction) and high-dose approaches, particularly relevant in the fentanyl era. I outline step-by-step protocols for various care settings and explain how we manage special populations, including pregnant, perioperative, and adolescent patients, as well as the integration of long-acting injectables like Sublocade and Brixadi.

A significant focus will be placed on our unique, multidisciplinary approach at Injury Medical Clinic PA. I explain how our team, under the medical direction of Dr. Maria Guadalupe Cardenas, MD, an internist with over 40 years of experience, integrates integrative chiropractic care, functional medicine, and conventional medical oversight to provide comprehensive, patient-centered care. This post covers transdermal (Butrans), buccal (Belbuca), and off-label sublingual buprenorphine for chronic pain; explores neurobiology, endocrine, and immune considerations; and illustrates our protocols for harm reduction, patient safety, and functional restoration for individuals navigating the complexities of OUD, chronic pain, and personal injury.

A Collaborative Vision for Healing: Integrating Medicine and Chiropractic Care

Welcome. My name is Dr. Alex Jimenez, and I am a Doctor of Chiropractic (DC) who has also pursued advanced training as an Advanced Practice Registered Nurse (APRN), a board-certified Family Nurse Practitioner (FNP-BC), and a certified practitioner in Functional Medicine (CFMP, IFMCP). My journey has been driven by a passion for understanding the intricate connections within the human body and finding the most effective, evidence-based paths to healing.

At our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) here in El Paso, Texas, we have cultivated a unique environment where different medical disciplines converge for the benefit of our patients. I am privileged to work alongside Dr. Maria Guadalupe Cardenas, MD, our Medical Director and Collaborative Physician. Dr. Cardenas is a highly respected, board-certified Internist with over four decades of clinical experience (NPI #1164426749, Texas MD License #J2933). Her profound knowledge of internal medicine provides the essential medical oversight that anchors our integrative model. This is a common, effective arrangement in integrative and injury care clinics: an MD provides medical direction alongside a chiropractor for comprehensive, coordinated care.

This multidisciplinary setup is foundational to how we approach complex conditions like chronic pain and personal injury. Our team combines:

• Medical Oversight (Dr. Cardenas): Providing diagnostic expertise, management of systemic health issues like cardiovascular risk and hepatic function, prescriptive authority, and supervision of all medical protocols.
• Chiropractic and Neuromusculoskeletal Care (Dr. Jimenez): Focusing on spinal health, biomechanics, nervous system function, manual therapy, and physical rehabilitation.
• Functional Medicine: Investigating the root causes of dysfunction and employing personalized nutrition, lifestyle interventions, and metabolic support.
• Personal Injury and Rehabilitation Services: Offering comprehensive care to restore function and well-being after an injury, including coordinated documentation and case management.

This collaborative framework allows us to create treatment plans that are not only holistic but also deeply personalized. When we discuss topics like opioid use and pain management, as we will today, it is through this integrated lens—seeing the patient as a whole person whose neuro-musculoskeletal health, biochemical state, and overall medical condition are inextricably linked.

Understanding the Modern Approach to Opioid Use Disorder (OUD)

Today, I want to take you on a journey into the complex world of Opioid Use Disorder (OUD) and chronic pain management. We will explore the latest findings from leading researchers, grounded in modern, evidence-based methods. This is not a formal lecture, but rather an educational discussion designed to be clear, comprehensive, and empowering.

Before we dive deep, I want to establish a few foundational points. First, the medication buprenorphine is a cornerstone of modern treatment. It is an FDA-approved, first-line therapy for Opioid Use Disorder. However, its utility doesn’t end there; certain formulations of buprenorphine are also approved to manage chronic pain. Throughout our discussion, we will carefully distinguish which formulations are appropriate for each indication, as this is critical to safe and effective care.

Second, it is essential to recognize that substance use disorders are fundamentally psychiatric diagnoses. As such, behavioral interventions, counseling, and psychotherapy are mainstays of comprehensive treatment. My focus today, however, will be primarily on the pharmacological aspect—the medications used to treat OUD. This is my area of deep clinical interest, and it’s vital because access to life-saving medication can depend on a patient’s participation in a behavioral program. People come to us at various stages of readiness and with different capacities to engage in treatment. As effective clinicians, our primary responsibility is to meet people where they are, providing the specific type and level of care they are willing and able to receive at that moment.

Why Medication-Assisted Treatment is Life-Saving: A life-saving question we must address is a fundamental one: Why do we use medications to treat Opioid Use Disorder? The answer is clear and backed by a mountain of scientific evidence.

• Reduces Mortality: First and foremost, medication for OUD is a life-saving intervention that significantly reduces the staggering rates of opioid-associated mortality. The data unequivocally show that patients engaged in medication-assisted treatment have a dramatically lower risk of fatal overdose compared to those who are not.
• Treats Withdrawal and Cravings: Both methadone and buprenorphine are incredibly effective at managing the two most formidable barriers to recovery: acute withdrawal symptoms and persistent, overwhelming cravings for opioids. The physical agony of withdrawal—the nausea, muscle cramps, sweating, and anxiety—can be unbearable. Cravings, a powerful neurobiological drive, can hijack a person’s thoughts and intentions, making relapse almost inevitable without support. By stabilizing the brain’s neurochemistry, these medications alleviate these symptoms, giving the patient the physiological stability needed to focus on recovery.
• Enables a Return to Life: By effectively treating the core symptoms of the disease, these medications empower patients to reclaim their lives. This isn’t just about stopping drug use; it’s about restoring function. It’s about being able to hold a job, rebuild relationships with family and friends, pursue hobbies, and engage in all the meaningful aspects of living that the disorder had stolen.

The Pharmacology of Healing: Understanding Mu-Opioid Receptor Activity

To truly grasp how these medications work, we need to venture into pharmacology and understand how they interact with the brain’s mu-opioid receptors. These receptors are part of the body’s natural pain-modulating system. Located throughout the central nervous system, they play a crucial role in regulating pain perception, mood, reward, and even essential autonomic functions like respiration. When opioids bind to these receptors, they produce a range of effects, from pain relief (analgesia) to euphoria and, at high doses, dangerous respiratory depression.

FDA-approved medications for OUD can be categorized by how they interact with these mu-receptors. Imagine a graph where the vertical (Y) axis represents the degree of opioid effect—the “intrinsic activity”—from 0% to 100%. The horizontal (X) axis represents the drug dose, increasing from left to right.

Full Agonists: The Methadone Profile

At the top of this graph are the full agonists, with methadone as the classic example.

• Mechanism: A full agonist binds to and fully activates the mu-opioid receptor. As the dose of methadone increases, the opioid effect also increases linearly until it reaches the maximum possible effect (100% receptor activity).
• Clinical Application: This property makes methadone highly effective for managing severe withdrawal and cravings in individuals with high levels of opioid tolerance. A properly titrated dose provides a steady, long-lasting effect that prevents withdrawal and blocks the euphoric effects of other opioids like heroin or fentanyl. However, this full agonism also carries a significant risk. At high doses, or when combined with other central nervous system depressants, methadone can cause profound respiratory depression, which can be fatal. For this reason, methadone treatment is tightly regulated and typically dispensed daily through specialized clinics.

Partial Agonists: The Buprenorphine Advantage

In the middle of our graph are the partial agonists, represented by buprenorphine. This is where the pharmacology becomes particularly interesting and advantageous.

• Mechanism: Buprenorphine also binds to the mu-opioid receptors, but it activates them only partially. As the dose of buprenorphine increases, the opioid effect rises, but only up to a certain point. It then hits a plateau, or a “ceiling effect.” Even if the dose continues to increase and all the mu-receptors become occupied by buprenorphine, the maximum opioid effect is never achieved.
• The Safety “Ceiling”: This ceiling effect is a game-changer for safety. The most dangerous side effect of opioids—respiratory depression—occurs at levels of receptor activation that are above buprenorphine’s plateau. This means buprenorphine carries a much lower intrinsic risk of causing a fatal overdose compared to full agonists like methadone or heroin. This superior safety profile is a primary reason why buprenorphine can be prescribed in office-based settings, including our own integrative practice, allowing for greater patient autonomy and accessibility.

Antagonists: The Naltrexone Blockade

Finally, at the very bottom of the graph, hugging the X-axis, we have the opioid antagonists, such as naltrexone.

• Mechanism: An antagonist binds strongly to the mu-opioid receptors but produces zero intrinsic activity. It essentially acts as a blocker. It occupies the receptor, preventing any agonist (like heroin, fentanyl, or even buprenorphine) from binding and producing an effect. Regardless of the dose, naltrexone itself produces no opioid effect.
• Clinical Application: Because it blocks opioid effects, naltrexone can be an effective tool for preventing relapse in highly motivated individuals who have already completed detoxification. However, it is crucial to understand that it provides no relief from cravings or withdrawal symptoms. In fact, if given to someone who is physically dependent on opioids, it will trigger an immediate and severe withdrawal syndrome. Furthermore, as it produces no mu-opioid activity, naltrexone is completely ineffective for pain management.

A Deeper Dive into Buprenorphine for Opioid Use Disorder

Now that we have a foundational understanding of its pharmacology, let’s focus specifically on buprenorphine and its use in treating OUD.

Navigating the Terminology: Buprenorphine Formulations

The term “buprenorphine” is often used as a catch-all. Still, it’s vital for us as clinicians and for you as a patient to understand the different formulations available, as they have different components and indications.

• Mono-Products (Buprenorphine Only): These formulations contain only buprenorphine as the active ingredient.

• • Subutex: A sublingual (under-the-tongue) tablet approved for the treatment of OUD.
  • Butrans: A transdermal patch applied to the skin, approved only for chronic pain management.
  • Belbuca (Buccal): A film placed on the inside of the cheek, also approved only for chronic pain.

• Combination Products (Buprenorphine/Naloxone): These are the most commonly prescribed formulations for OUD.

• • Suboxone, Zubsolv, Cassipa: These are brand names for products that combine buprenorphine with naloxone. They come in sublingual films or tablets.
  • The Role of Naloxone: The naloxone component in these combination products is an important safety and diversion-deterrent feature. When the film or tablet is taken as directed (sublingually), the naloxone is not readily absorbed into the bloodstream and has no effect. The buprenorphine is absorbed and works as intended. However, if a person crushes the tablet or dissolves the film and injects it, the naloxone would be absorbed immediately. As an opioid antagonist, it would rapidly displace other opioids from the receptors and induce precipitated withdrawal—a sudden, severe, and intensely unpleasant withdrawal syndrome. This mechanism strongly discourages misuse of the medication via injection.

When to Choose a Mono-Product Over a Combination Product

While the combination products are the standard of care, some patients experience side effects even when taking them correctly. A small amount of naloxone can still be absorbed sublingually, and for sensitive individuals, this can lead to headaches or gastrointestinal upset (like nausea or constipation). In my clinical practice, I maintain a very low threshold for switching a patient from a combination product (e.g., Suboxone) to a mono-product (e.g., Subutex) if they report these side effects. Patient comfort and adherence are paramount.

However, this decision comes with practical considerations. Some insurance plans are more reluctant to cover the mono-product for OUD, and some community pharmacies or providers may be hesitant to prescribe it due to outdated concerns about diversion risk. Before starting a patient on a mono-product, it’s my responsibility to ensure seamless continuity of care—either by continuing the prescription myself or by confirming they have a provider who will.

• Long-Acting Injectable Buprenorphine: In recent years, we’ve seen the development of long-acting injectable (LAI) formulations, which have revolutionized treatment for many.

• • Sublocade and Brixadi (Injectable): These are administered as a subcutaneous injection (under the skin) by a healthcare provider, typically monthly. The medication forms a solid depot from which buprenorphine is slowly and consistently released over the month.
  • Benefits: LAIs eliminate the need for daily dosing, reducing the burden of remembering to take medication, lowering the risk of diversion or missed doses, and providing very stable plasma levels of buprenorphine. This can lead to superior craving control and allows patients to focus more fully on other aspects of their recovery without the daily reminder of their medication.

Clarifying Indications: OUD vs. Chronic Pain

To avoid confusion, let’s clearly summarize the FDA-approved indications for these different products.

• For Opioid Use Disorder (OUD) and Opioid Withdrawal:

• • Subutex (buprenorphine sublingual tablet)
  • Suboxone and other combination products (buprenorphine/naloxone sublingual films/tablets)
  • Sublocade (buprenorphine monthly injection)
  • Brixadi (buprenorphine weekly/monthly injection)

• For Chronic Pain:

• • Butrans (buprenorphine transdermal patch)
  • Belbuca (buprenorphine buccal film)
  • Buprenex (injectable buprenorphine, typically used for acute pain in controlled settings)

It is also important to note a common and valuable off-label practice. We frequently see sublingual formulations like Subutex and Suboxone used for the treatment of chronic pain, especially in patients who have developed complex persistent opioid dependence or have a concurrent OUD. This is where the art and science of medicine intersect, tailoring treatment to the individual’s complex needs.

Practical Guidance for Administration and Patient Counseling

Proper administration of sublingual buprenorphine is crucial for its effectiveness. I always take the time to counsel my patients on the correct technique.

• Sublingual Administration Technique:

• • Place the tablet or film under the tongue and allow it to dissolve completely.
  • Keep it there for at least 10 minutes, without talking, eating, or drinking.
  • The medication is absorbed through the rich network of blood vessels in the mouth’s mucosal lining, directly into the bloodstream. It does not need to be swallowed or go through the stomach.
  • Managing Nausea: Some patients experience nausea after dosing. If this occurs, I advise them to spit out the saliva that accumulates as the medication dissolves. The active ingredient will still be absorbed, but this can prevent the GI upset that sometimes occurs when the saliva is swallowed.

The Informed Consent Discussion: Setting the Stage for Success

Before initiating buprenorphine for OUD, a thorough and transparent informed consent discussion is not just a formality—it is the foundation of a trusting therapeutic relationship. This is a shared decision-making process.

1. Confirm the Diagnosis: First, we must ensure the patient meets the clinical criteria for both Opioid Use Disorder (as defined by the DSM-5) and is experiencing, or is at high risk for, acute opioid withdrawal.
2. Explain the Nature of Buprenorphine: I am very direct with my patients about this: Buprenorphine is a form of opioid. By taking it, they will become physically dependent. This is not the same as addiction (which involves compulsive, harmful use), but it does mean that if they were to stop it abruptly, they would experience a withdrawal syndrome. We discuss that it can be a challenging medication to discontinue, and this is a long-term treatment commitment.
3. Consider Alternatives: This is especially important if a patient has a mild OUD or if the primary issue is chronic pain. Have we truly exhausted all other non-opioid options for pain management? This is where our integrative model shines. We can explore chiropractic adjustments to improve spinal mechanics, physical therapy, acupuncture, anti-inflammatory nutrition, and other modalities before committing to long-term opioid therapy.
4. Critical Counseling Points:

• • Initiation Timing and Precipitated Withdrawal: This is perhaps the most critical point. I explain in detail that buprenorphine must be started only when they are already in a state of moderate opioid withdrawal. If taken too soon, while other full agonist opioids are still attached to their brain’s receptors, the buprenorphine (with its higher binding affinity) will aggressively displace those opioids and trigger precipitated withdrawal. We will discuss this phenomenon in much greater detail shortly.
  • Proper Administration: I review the sublingual technique we just discussed.
  • Physical Dependence: I review the concept of physical dependence and the need for a slow, medically supervised taper if they ever decide to discontinue the medication.
  • Dental Health Risks: There is an FDA warning and case reports associating buprenorphine medications dissolved in the mouth with an increased risk of dental caries (cavities), infections, and tooth erosion. The medication’s acidic nature and its tendency to cause dry mouth can contribute to this. I counsel my patients that this risk can be significantly mitigated by practicing good dental hygiene: rinsing the mouth with water after the medication has dissolved, waiting at least an hour before brushing, and maintaining regular dental visits.
  • Liver Health: Buprenorphine is metabolized by the liver. For patients with pre-existing or acute liver impairment (e.g., hepatitis with acutely elevated liver enzymes), we need to proceed with caution. I recommend baseline liver function tests and follow-up monitoring to ensure the liver is metabolizing the drug effectively. In severe liver impairment, the drug can accumulate, increasing the risk of sedation and respiratory depression.
  • The Risk of Combining with Other Depressants: I am emphatic about this safety issue. While overdose from buprenorphine alone is rare due to its ceiling effect, the risk increases dramatically when it is combined with other central nervous system depressants. The most common and dangerous combinations are with alcohol and benzodiazepines (like Xanax, Valium, or Klonopin). This combination can override the safety ceiling of buprenorphine and lead to life-threatening respiratory depression.

The Critical Moment: Buprenorphine Initiation in the Fentanyl Era

I have spent many years helping patients transition from full-agonist opioids to buprenorphine. In the fentanyl era, this work has become more challenging, but also more essential. Buprenorphine remains one of the safest, most effective treatments for OUD, but the clinical reality is more nuanced than “start the medication.” Let’s walk through the step-by-step process of buprenorphine induction, explore the physiology of precipitated withdrawal, and discuss innovative new strategies that are making this process safer and more comfortable for our patients.

What Is Precipitated Withdrawal and Why We Must Prevent It

I always begin by explaining precipitated withdrawal, because understanding it empowers patients to choose an induction pathway that fits their physiology and goals.

• Definition: Precipitated withdrawal is the rapid onset of objective opioid withdrawal signs shortly after the first buprenorphine dose. Patients often describe it as “the worst withdrawal I’ve ever had.”
• Typical signs: Pupillary dilation, piloerection (gooseflesh), extreme restlessness, vomiting, diarrhea; clinically, we often see a sudden rise in the Clinical Opioid Withdrawal Scale (COWS) score by ≥5 points after dosing.
• Subjective experience: Patients often report overwhelming anxiety, agitation, and the inability to sit still—feeling compelled to leave the exam room immediately.

Why it happens: receptor pharmacology in plain language

• Mu-opioid receptors can be occupied by:

• • Nothing (white circle in the mental picture): patient feels withdrawal.
  • Full agonists (red circle): heroin, oxycodone, fentanyl—suppress withdrawal by strongly activating receptors.
  • Buprenorphine (dark blue circle): a high-affinity partial agonist—it binds very tightly, displacing full agonists, but does not activate the receptor to the same degree.

• If buprenorphine is introduced when full agonists are still heavily occupying receptors, it “kicks them off” but provides less activation, creating a net drop in opioid effect and a sudden, severe withdrawal.

Key insight: Avoiding precipitated withdrawal means introducing buprenorphine when full-agonist signaling is already sufficiently reduced (traditional and high-dose methods) or introducing buprenorphine gradually while full agonists taper across the receptors (low-dose method).

Fentanyl Changes the Induction Landscape

Illicitly manufactured fentanyl (IMF) is potent, lipophilic, and omnipresent. This matters for induction in several ways:

• Lipophilicity and tissue reservoirs: Fentanyl sequesters in fat and can leach out slowly, leading to delayed receptor re-occupation after apparent abstinence. Clinically, we may see withdrawal begin on schedule, but precipitated withdrawal can still occur later than expected if buprenorphine is given too early for the tissue kinetics involved (Huhn et al., 2020; Khatri & Viner, 2022).
• Clinical phenotype: Patients withdrawing from fentanyl often present with outsized restlessness and anxiety, sometimes out of proportion to other withdrawal signs, which can be misattributed to primary anxiety disorders if we are not vigilant.
• Patient history: Many have attempted buprenorphine before and experienced withdrawal or precipitated withdrawal. Their lived experience and preferences must guide the choice of induction method.

These realities push us to consider low-dose or high-dose strategies more often and to emphasize shared decision-making.

Framework for Choosing an Induction Strategy

I offer three primary methods, each appropriate in specific contexts. There is no one “best” approach for all patients—especially in the fentanyl era.

• Traditional induction
• Low-dose (micro-induction) induction
• High-dose induction

We individualize using:

• Time since last full-agonist use.
• Current withdrawal severity (COWS) and objective signs.
• Patient preferences, past experiences, and setting (ED, inpatient, clinic).
• Co-morbid pain, anxiety, and sleep issues.
• Logistics (care coordination, follow-up capabilities).
• Payer constraints (dose caps or prior authorization issues).

ASAM’s 2023 clinical considerations emphasize individualized induction aligned with setting and patient preference; low-dose starts are well tolerated in hospitals but less studied in ambulatory care; symptom-targeted co-medications can aid mild-to-moderate withdrawal; and patients using high-potency synthetic opioids may require more than 16 mg/day, sometimes above 24 mg/day for stabilization (ASAM, 2023).

Shared Decision-Making: Patients Are Authorities on Their Bodies

Our Oregon-based colleagues have illuminated how autonomy and individualization improve initiation success. I echo their findings in daily practice: when I present options transparently, patients choose methods that respect their discomfort thresholds, schedules, and safety concerns. Patients who prioritize “avoiding any withdrawal” lean toward low-dose induction. Those who want a swift, decisive transition—often after a failed slow start—may choose high-dose once adequately withdrawn. Traditional induction remains suitable for select patients not using fentanyl or on predictable short-acting opioids.

Patient guidance insights I routinely discuss:

• “Flu-like” is an incomplete description of withdrawal: the crushing anxiety, dysphoria, and restlessness can be the most disabling elements. We plan for them.
• COWS is useful but imperfect: we should pair it with patient-reported experience, especially with fentanyl’s anxiety-dominant withdrawal profile.
• Adjunctive medications can smooth the path and are part of evidence-based care.

Symptom-Targeted Medications: Why and When I Use Each

• Clonidine: Reduces adrenergic hyperactivity (restlessness, anxiety, sweating, tachycardia). By agonizing alpha-2 receptors, clonidine dampens locus coeruleus firing, addressing the sympathetic surge central to withdrawal distress (Gowing et al., 2016).
• Tizanidine: Alpha-2 agonist with muscle relaxant properties helpful for cramps and global myalgia—particularly useful in patients with hypertonic paraspinals or myofascial pain that flares during withdrawal. It synergizes with chiropractic soft-tissue work by reducing reflexive muscle guarding.
• Hydroxyzine: Antihistamine with anxiolytic and sedative properties; valuable for anxiety, restlessness, itching, and sleep initiation. It can reduce reliance on benzodiazepines, which we avoid during OUD inductions.
• Trazodone: Non-habit-forming sleep aid that helps patients maintain nocturnal rest as autonomic symptoms abate, improving daytime tolerance of induction.
• NSAIDs and acetaminophen: Anti-inflammatory and analgesic support when musculoskeletal pain is prominent. They are essential in injury clinics where nociceptive drivers complicate withdrawal.
• Ondansetron: 5-HT3 antagonist for nausea/vomiting; improves adherence by allowing sublingual buprenorphine to be retained and absorbed.
• Loperamide: Symptom relief for diarrhea; targeting enteric mu receptors without central penetration at labeled doses.

These choices follow the principle: reduce autonomic overdrive, stabilize sleep, and address pain to improve tolerance of induction and reduce the risk of abandonment.

The Three Primary Buprenorphine Initiation Methods: How I Do Them and Why

Traditional Induction: When Simplicity and Predictability Fit

Best for:

• Patients transitioning from known short-acting opioids (e.g., oxycodone) without fentanyl adulteration.
• Patients who can tolerate moderate withdrawal and want a straightforward, familiar path.

Requirements:

• Abstinence windows:

• • Short-acting opioids (e.g., oxycodone): 12–24 hours.
  • Long-acting/methadone: 24–72 hours.
  • Fentanyl: at least 48 hours—but in practice, this is hard to achieve and risky due to delayed precipitated withdrawal.

• Use objective measures (COWS ≥8–12) to guide timing.

Start and titration:

• Begin when at least mild-to-moderate withdrawal is present; the more severe the withdrawal at initiation, the greater the immediate relief after dosing.
• Initial dose: 2–8 mg buprenorphine, then 2–8 mg every 2–4 hours up to 16–24 mg on day 1, based on persistent symptoms.

Advantages:

• Familiar, well-studied; no cutting films or tablets.
• Less care coordination than low-dose induction.
• Works well in predictable pharmacologic contexts.

Disadvantages:

• In fentanyl users, risk of precipitated withdrawal remains elevated even after typical abstinence windows.
• Low initial doses may not adequately blunt withdrawal for fentanyl users.
• Patients often cannot tolerate the prolonged pre-induction withdrawal period.

Low-Dose (Micro-Induction) Buprenorphine: Gradual Receptor Transition Without Withdrawal

Best for:

• Patients prioritizing withdrawal avoidance.
• Individuals using fentanyl or long-acting opioids where precipitated withdrawal is a major risk.
• Patients with acute pain requiring concurrent full-agonist management.

How it works:

• Introduce very small doses of buprenorphine while the patient continues full-agonist opioids; buprenorphine’s high affinity slowly displaces full agonists, increasing receptor occupancy over days without a sudden drop in signaling.

Four-day example (fastest ambulatory schedule I use):

• Day 1: total 0.5–1 mg in divided doses while continuing full-agonist opioid.
• Day 2: total 2–4 mg while continuing full-agonist opioid.
• Day 3: total 6–8 mg while continuing full-agonist opioid; counsel on overdose prevention because protection rises meaningfully around 8 mg/day.
• Day 4: 12–16 mg; stop full agonist once buprenorphine occupancy is adequate; continue titration as needed.

Six- to seven-day example (slower, gentler):

• Start at 0.5 mg/day total and increase daily to 12 mg by day 7; crossover when the patient reports craving suppression and adequate withdrawal control.

Why I sometimes prefer slower:

• Patients with prior micro-induction withdrawals, high fentanyl exposure, or fragile autonomic balance benefit from gradual up-titration.
• Allows real-time adjustments, builds patient confidence, and supports coordinated pain and anxiety management.

Advantages:

• Minimizes precipitated withdrawal risk.
• Most comfortable option for many fentanyl users.
• Compatible with concurrent analgesia, crucial in injury and postoperative settings.

Disadvantages:

• Complexity: requires splitting films or tablets; intensive patient education and frequent touchpoints.
• Continued full-agonist use for several days necessitates harm-reduction counseling; patients must commit to a quit date.
• Outpatient success rates can be modest if patients lack support; clinic accessibility and daily coaching raise success.

High-Dose Induction: Swift Stabilization With Adequate Withdrawal

Best for:

• Patients in ED/urgent care or clinic who present in clear withdrawal and want a rapid, decisive transition.
• Fentanyl users whose withdrawal is sufficiently advanced to minimize precipitated withdrawal risk.

Process:

• Confirm abstinence window as feasible (fentanyl ≥12 hours is a pragmatic minimum, but clinical signs matter more).
• Assess COWS; I typically require ≥16 and at least two objective signs (dilated pupils, piloerection, rhinorrhea, diarrhea).
• Dose: 8–16 mg initially (I lean toward 16 mg for fentanyl users); reassess after ~30 minutes.
• If tolerated, give additional 8 mg increments to a total of up to 32 mg on day 1.
• Day 2: continue 24–32 mg/day, then taper to the lowest effective maintenance dose once stabilized.

Rationale:

• High receptor occupancy early suppresses withdrawal and craving, outpacing fentanyl’s tissue kinetics.
• A single dose size simplifies instructions and reduces errors.
• Bridging research and pragmatic ED protocols (e.g., CA Bridge) support safety and effectiveness for appropriate candidates.

Advantages:

• Rapid stabilization and clear symptom relief.
• Simple dosing; fewer moving parts than micro-induction.
• Useful in acute care settings where observation is possible.

Disadvantages:

• If precipitated withdrawal occurs, it can be severe due to larger doses.
• Requires careful screening for objective withdrawal signs and patient education.

How Integrative Chiropractic Care Complements OUD and Pain Treatment

You might be wondering how chiropractic care fits into this picture. At Injury Medical Clinic PA, the integration is seamless and synergistic. When a patient is stabilized on a medication like buprenorphine, the physiological chaos begins to subside. This is the window of opportunity where our other therapies can have a profound impact.

• Addressing the Physical Toll of Addiction: Chronic substance use and the associated lifestyle often lead to significant musculoskeletal problems. Poor posture, nutritional deficiencies, lack of exercise, and physical trauma can result in chronic back pain, neck pain, headaches, and joint issues.
• Chiropractic Adjustments: Gentle, specific chiropractic adjustments can help restore proper spinal alignment and joint mobility. This improves nervous system function, reduces pain signals, and alleviates physical stress on the body. For a patient in recovery, feeling physically better can be a massive psychological boost and can reduce the temptation to self-medicate with illicit substances.
• Autonomic Modulation: Gentle mobilization, soft tissue techniques, and breathing-centered sessions help downregulate sympathetic overdrive and reduce withdrawal-related anxiety and hyperalgesia.
• Functional Medicine and Nutrition: We use functional medicine principles to assess and correct underlying nutritional deficiencies and gut health issues, which are rampant in this population. A nutrient-dense, anti-inflammatory diet can help heal the brain, balance neurotransmitters, reduce systemic inflammation, and improve energy levels and mood.
• Rehabilitation and Movement: Our rehabilitation programs focus on restoring strength, flexibility, and proper movement patterns. Exercise is a potent tool for recovery; it releases endorphins, reduces stress, improves sleep, and helps rebuild a healthy relationship with one’s own body.

Under the watchful eye of Dr. Cardenas, who manages the patient’s overall medical status, we can confidently apply these therapies. This integrated approach ensures that we are not just treating the addiction or the pain in isolation; we are treating the whole person, helping them rebuild their health from the ground up on a physical, biochemical, and structural level.

Long-Acting Injectable Buprenorphine: Sublocade and Brixadi

Long-acting injectable (LAI) buprenorphine formulations have become powerful tools in our clinic, offering stability and simplifying treatment for many patients.

Advantages

• Stable plasma levels: Reduced peaks and troughs compared to daily SL dosing, minimizing daily cycles of mini-withdrawal and cravings.
• Improved adherence: Monthly or weekly dosing simplifies routines, reduces diversion risk, and may enhance retention.
• Potential overdose protection: Continuous receptor occupancy may offer theoretical benefits; research is ongoing.
• Facilitation of tapers: In select cases, long-acting formulations can help buffer tapering discomfort.

Disadvantages and Considerations

• Injection site reactions: Local erythema, firmness, or tenderness; counsel patients and use technique optimization.
• Cost and coverage: Variable coverage; billing processes can be complex; we assist patients with authorizations and alternatives.
• Provider availability: Requires trained administrators; our clinic maintains protocols and staff training to ensure safe and consistent delivery.

Sublocade: Monthly Extended-Release Buprenorphine

• Initiation protocol: Patients must first tolerate a minimum of 8 mg/day of sublingual buprenorphine to reduce precipitated withdrawal risk.
• Dosing: Initial doses commonly start at 300 mg monthly, followed by ongoing doses of 100–300 mg depending on history and tolerance.
• Steady state: Reached at 4–6 months—an essential counseling point. Patients may need supplemental sublingual doses during the early months.
• Patient education: We emphasize the lag to full effect, the rationale for occasional supplemental SL dosing, and how this regimen supports stabilization.

Brixadi: Weekly and Monthly Options

• Flexibility: Offers weekly or monthly dosing; weekly is useful early when symptoms fluctuate.
• Direct weekly initiation in withdrawal: Emerging evidence suggests weekly injectable initiation may be feasible in acute withdrawal contexts, particularly ED/urgent care, with supplemental dosing. This must be done in appropriate settings with monitoring and follow-up.
• Serum level dynamics: Levels may fall toward the end of the month before steady state; supplemental dosing at month’s end can be helpful.
• Counseling: Set expectations about steadiness, possible “end-of-cycle” dips initially, and the need for short-term adjunct support.

Special Populations: Detailed Guidance

Treating OUD requires tailoring our approach to the unique physiological and social needs of different patient populations.

Pregnancy

• Buprenorphine is the recommended first-line treatment for OUD during pregnancy, using sublingual formulations.
• Physiologic changes: Increased volume of distribution, enhanced hepatic metabolism, and renal changes can necessitate higher or split dosing to maintain blockade and comfort.
• Care points:

• • Shared decision-making with obstetrics and addiction specialists.
  • Regular assessment of withdrawal and cravings, maternal vitals, and fetal well-being.
  • Non-pharmacologic supports: Gentle chiropractic mobilization avoiding high-velocity thrusts, postural supports, pelvic floor coordination, and sleep positioning.

Perioperative Patients

• Continue buprenorphine through the perioperative period; discontinuation increases relapse risk and complicates pain control.
• Coordination with anesthesia:

• • Potential dose adjustments: Some scenarios favor dose increases or split dosing to enhance analgesic coverage.
  • Multimodal analgesia: Regional anesthesia, acetaminophen, NSAIDs, ketamine, gabapentinoids, and non-pharmacologic strategies are essential.

• Chiropractic integration: Prehab to optimize biomechanics and breathing mechanics; post-op gentle mobilization when appropriate.

Adolescents (≥16 years)

• Buprenorphine is FDA-approved for first-line treatment in adolescents 16 and over.
• Blockade threshold: 8 mg SL is often cited as the lowest typical blockade dose for overdose protection; individual titration is essential.
• Counseling:

• • Clear, concise messaging: Emphasize safety, adherence, and naloxone.
  • Family engagement: Educate caregivers on storage, dosing, monitoring, and emergency naloxone use.
  • Activity restoration: Supervised exercise and posture coaching to reinforce healthy routines.

Methadone: Full Agonist Treatment for OUD—Mechanisms and Clinical Practice

While our office-based practice focuses on buprenorphine, it’s crucial to understand methadone’s role as another evidence-based, life-saving option. Work closely with licensed Opioid Treatment Programs (OTPs) for patients for whom methadone is the more appropriate choice.

Mechanistic Overview

• Full mu agonist: Provides strong receptor activation, suppresses withdrawal, stabilizes cravings, and supports long-term recovery for many patients.
• Pharmacokinetics:

• • Long and variable half-life (8–65 hours); steady state reached in 4–7 days, necessitating careful, slow titration.

• QTc Considerations:

• • Methadone prolongs the QTc interval on an ECG; baseline screening is reasonable, especially with risk factors. Dr. Cardenas oversees this medical monitoring.

• Legal and Access Framework (United States):

• • Licensed OTPs must dispense outpatient methadone for OUD. We facilitate referrals and bridge care.

Naltrexone: Antagonist Therapy for OUD—Role and Limitations

Naltrexone is an opioid antagonist, which means it blocks opioid receptors without activating them.

• Mechanism: Pure opioid antagonist; blocks mu receptors to prevent opioid effects but does not treat withdrawal or cravings.
• Induction requirement: Patients must be opioid-free for 7–10 days before initiation to avoid precipitated withdrawal.
• Dosing:

• • Oral: 50 mg daily.
  • IM (Vivitrol): 380 mg every 4 weeks.

• Pain management caveat: Concurrent opioid analgesia will be blocked. This is a critical consideration for patients with chronic pain or those anticipating surgery.

Buprenorphine for Chronic Pain Management: A Safer Alternative

Now, let’s shift our focus to using buprenorphine specifically for chronic pain. Its unique pharmacology makes it a valuable and often safer alternative to full agonist opioids.

Why Buprenorphine Is Different: Modern Pharmacology and Reduced Risk Profile

• Partial μ-agonism with high affinity: Buprenorphine binds tightly to μ-opioid receptors, but its partial activation caps respiratory depression and blunts extreme euphoric reinforcement compared with full agonists (Lintzeris et al., 22; Volkow et al., 2014).
• Reduced risk of opioid-induced hyperalgesia (OIH): Full μ-agonists can paradoxically increase pain sensitivity over time. Buprenorphine is less likely to trigger or perpetuate OIH (Chu et al., 2006; Angst & Clark, 2006).
• Lower sedation and milder withdrawal: My patients often report greater clarity and less sedation when switching from full agonists. Physical dependence: Patients can depend on the drug; withdrawal tends to be milder when properly tapered.
• Potential mood and depression benefits: In select patients, I have observed mood stabilization after buprenorphine rotation, potentially via its complex receptor activity (Fava et al., 2016; Ehrich et al., 2015).
• Lower incidence of adverse effects: Compared to full agonists, buprenorphine is associated with lower rates of falls, hypogonadism (low testosterone), immunosuppression, and cognitive impairment (Daniell, 2002; Huhn et al., 2019).

Selecting the Right Patient: Practical Criteria and Clinical Reasoning

When I consider buprenorphine for chronic pain, I follow a structured process.

• Exhaust non-opioid options first: We prioritize multimodal strategies like physical and chiropractic care, non-opioid analgesics, interventional options, and mind-body therapies before considering any long-term opioid.
• Identify high-risk patients for full agonists: Buprenorphine is particularly valuable for:

• • Patients with repeated falls, sedation, or cognitive impairment on full agonists.
  • Patients with hypogonadism, osteoporosis, or sleep apnea.
  • Patients struggling with tapers or with suspected OIH.

• Evaluate previous opioid exposure: We use a practical algorithm based on a patient’s daily Morphine Milligram Equivalent (MME).

• • If >100 MME/day or diagnosed OUD: Sublingual buprenorphine is usually indicated.
  • If <100 MME/day: Transdermal or buccal formulations may be effective.

Transdermal Buprenorphine (Butrans): Dosing and Practical Considerations

The buprenorphine transdermal patch (Butrans) is FDA-approved for pain and can be effective for patients on lower-dose opioids.

• Pre-rotation: We typically taper to <30 MME/day before starting Butrans.
• Starting doses:

• • <30 MME/day: start 5 mcg/hr
  • 30–80 MME/day: start 10 mcg/hr

• Application guidance: Wear the patch for 7 days, rotating sites on hairless skin. Avoid direct heat (e.g., heating pads), which can increase absorption and risk.

Buccal Buprenorphine (Belbuca): Flexible Dosing and Enhanced Bioavailability

The buccal film (Belbuca) allows for more flexible dosing.

• Dosing range: 75 mcg up to 900 mcg every 12 hours.
• Starting dose by prior opioid exposure:

• • <30 MME/day: 75 mcg every 12 hours
  • 30–89 MME/day: 150 mcg every 12 hours
  • ≥90 MME/day: 300 mcg every 12 hours

• Clinical tips: Buccal film is useful when patches cause skin irritation or when patients need more dose granularity.

Off-Label Sublingual Buprenorphine in Chronic Pain

Sublingual buprenorphine is often considered off-label for analgesia in complex chronic pain cases, especially when MME is very high or when OUD is also present.

• Indications: Typically for patients on ≥100–160+ MME/day with inadequate relief or those who have failed transdermal/buccal formulations.
• Safety: We counsel patients on its high affinity (potential for precipitated withdrawal) and ensure a careful, coordinated rotation from their full agonist.

Harm Reduction and Overdose Prevention: A Compassionate, Evidence-Based Framework

Our clinic embraces harm reduction as a practical, evidence-based approach to reduce negative outcomes associated with substance use.

Core messages I share with patients:

• Illicit opioids often contain fentanyl: This dramatically increases overdose risk.
• Carry naloxone (Narcan) at all times: We prescribe naloxone to at-risk patients and train them and their families on how to use it.
• Route matters: While smoking fentanyl may reduce some risks compared to injecting, it still carries substantial overdose risk. If injecting, we teach hygienic techniques to prevent infection.
• Abstinence is not a precondition for help: We meet patients where they are and offer pathways to treatment whenever they are ready.
• Test doses and never use alone: Especially with potential fentanyl contamination, start with a test dose and avoid using alone.

Clinical Observations From My Practice

From my clinical experiences and case logs, I’ve seen clear patterns emerge that align with current research:

• Patients transitioning to buprenorphine frequently report mental clarity, better sleep, and more stable pain—often within 2–4 weeks—a window where my chiropractic and rehab protocols show improved consistency and effectiveness.
• Fentanyl-exposed patients often succeed with slower micro-inductions when paired with daily check-ins, clear written dosing plans, and adjunct medications. The key is predictable contact and reinforcement.
• High-dose induction works very well when we confirm robust objective withdrawal. The immediate relief builds trust quickly.
• Integrative care reduces early dropout. When patients feel their pain is being actively treated through chiropractic soft-tissue work and movement strategies, their tolerance for induction discomfort increases.
• Anxiety management is pivotal. Hydroxyzine and clonidine, coupled with breathing and sleep support, often redirect a failing induction into a successful one.
• Patients repeatedly report warm showers as immediate, effective relief for the muscle cramps and achiness common during induction.

More about my clinical observations and integrative approaches can be found on my website and professional profiles:

• https://dralexjimenez.com/
• https://www.linkedin.com/in/dralexjimenez/

Closing Thoughts: Compassionate, Science-Based Care Works

As a clinician and integrative provider, I witness daily the resilience of patients facing OUD and complex pain. When we combine evidence-based pharmacotherapy with internal medicine oversight, integrative chiropractic care, functional medicine, and coordinated rehabilitation, outcomes improve. We reduce suffering, stabilize lives, and enable healthier futures. Under the expert medical direction of Dr. Maria Guadalupe Cardenas, MD, our clinic provides a safe, structured environment where science, compassion, and practical support meet. If you are struggling with these issues, know that effective, evidence-based pathways can help you reduce pain, improve function, and live with more certainty and safety.

References

• American Society of Addiction Medicine. (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Journal of Addiction Medicine, 14(2S), 1–91.
• American Society of Addiction Medicine. (2023). Clinical considerations for buprenorphine initiation and stabilization in the era of fentanyl. ASAM.org.
• Angst, M. S., & Clark, J. D. (2006). Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology, 104(3), 570–587.
• Belbuca (buccal buprenorphine) Prescribing Information. (2019). BioDelivery Sciences International.
• Butrans (transdermal buprenorphine) Prescribing Information. (2019). Purdue Pharma.
• Cahill, C. M., et al. (2014). Delta-opioid receptor-mediated enhancement of excitatory neurotransmission in the anterior cingulate cortex. Journal of Neuroscience, 34(38), 12726–12737.
• Calder, P. C. (2015). Omega-3 fatty acids and inflammatory processes. Nutrients, 7(9), 6590–6610.
• Centers for Disease Control and Prevention. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recommendations and Reports, 71(3), 1–95.
• Chu, L. F., et al. (2006). Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clinical Journal of Pain, 22(5), 479–496.
• Dahan, A., et al. (2006). Buprenorphine induces a ceiling in respiratory depression but not in analgesia. British Journal of Anesthesia, 96(5), 627–632.
• Daitch, D., et al. (2019). Conversion from high-dose full-opioid agonists to sublingual buprenorphine: A strategy for chronic pain patients. Pain Medicine, 20(6), 1116–1123.
• Daniell, H. W. (2002). Hypogonadism in men consuming sustained-action oral opioids. Journal of Pain, 3(5), 377–384.
• Ehrich, J. M., et al. (2015). Kappa opioid receptor-induced aversion in mice. Neuropsychopharmacology, 40, 1903–1911.
• Fava, M., et al. (2016). A phase 3, multicenter, randomized, double-blind, flexible-dose, active-controlled study of buprenorphine-samidorphan in patients with major depressive disorder. Journal of Clinical Psychiatry, 77(6), 762–770.
• Gowing, L., Farrell, M., Ali, R., & White, J. M. (2016). Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, 2016(5), CD002024.
• Hawk, M., et al. (2017). Harm reduction principles and practice. Harm Reduction Journal, 14(1), 70.
• Huhn, A. S., et al. (2019). Comparative efficacy of available buprenorphine formulations for the treatment of opioid use disorder. JAMA Psychiatry, 76(6), 649–650.
• Huhn, A. S., Hobelmann, J. G., Oyler, G. A., & Strain, E. C. (2020). Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug and Alcohol Dependence, 214, 108147.
• Kampman, K., & Jarvis, M. (2015). American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. Journal of Addiction Medicine, 9(5), 358–367.
• Khatri, U. G., & Viner, K. (2022). Buprenorphine initiation in the era of fentanyl: Clinical challenges and opportunities. Annals of Emergency Medicine, 80(2), 108–113.
• Le Merrer, J., et al. (2009). Reward processing by the opioid system in the brain. Physiological Reviews, 89(4), 1379–1412.
• Lintzeris, N., et al. (2022). A randomized controlled trial of oral versus injectable extended-release buprenorphine for opioid use disorder. The Lancet, 399(10329), 1050–1060.
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, (2), CD002207.
• Pergolizzi, J. V., Jr., et al. (2013). The safety and efficacy of transdermal buprenorphine for the treatment of chronic pain. Journal of Pain Research, 6, 111–118.
• S. Food & Drug Administration. (2022, January 12). FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. FDA.gov.
• Volkow, N. D., & McLellan, A. T. (2016). Opioid abuse in chronic pain—misconceptions and mitigation strategies. New England Journal of Medicine, 374(13), 1253–1263.
• Volkow, N. D., et al. (2014). Medication-assisted therapies—tackling the opioid-overdose epidemic. New England Journal of Medicine, 370(22), 2063–2066.
• Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55(5), 569–580.
• White, J. M., & Irvine, R. J. (1999). Mechanisms of fatal opioid overdose. Addiction, 94(7), 961–972.

SEO Tags: Buprenorphine, Opioid Use Disorder, Chronic Pain Management, Integrative Chiropractic Care, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, El Paso Chiropractor, Functional Medicine, Methadone, Naltrexone, Precipitated Withdrawal, Suboxone, Subutex, Sublocade, Brixadi, buprenorphine induction, fentanyl precipitated withdrawal, low-dose micro-induction, high-dose buprenorphine, Medication-Assisted Treatment, Mu-Opioid Receptor, Shared Decision-Making, Personal Injury Clinic, Multidisciplinary Care, Harm Reduction, Buprenorphine Initiation, Pain Management, Spinal Health, Neuromusculoskeletal Care, OUD primary care, evidence-based addiction treatment, transdermal buprenorphine, buccal buprenorphine, opioid-induced hyperalgesia, ASAM guidelines, COWS scale, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic